Aiming to develop the next potential breakthrough for MASH
Inventiva is a clinical-stage biotechnology company developing a novel oral treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Our science uniquely aims to target MASH at its biological roots, simultaneously targeting the core drivers of MASH progression: metabolic dysfunction, inflammation, and fibrosis, in a single oral investigational therapy.
Now completing a global Phase 3 clinical trial, following positive results from our Phase 2b clinical trial in MASH. We are advancing our trials with confidence.
Stay up to date with the latest company news, clinical milestones, scientific presentations, and corporate developments as we continue advancing innovation in MASH.
